NASDAQ: SNSE - Sensei Biotherapeutics, Inc.

Yield per half year: -20.96%
Sector: Healthcare

Share chart Sensei Biotherapeutics, Inc.

Extended chart Simple chart
Financial Markets by TradingView

About

Sensei Biotherapeutics, Inc., an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. Its Tumor Microenvironment Activated Biologics platform is designed to unleash the anti-tumor potential of T cells, as well as human monoclonal antibodies that are selectively active in the tumor microenvironment and target immune checkpoints or other critical immune pathways. The company's pipeline includes SNS-101, SNS-103, and SNS-102, monoclonal antibodies, which are in early development stages for the treatment of solid tumors.

more details
It has a collaboration with The University of Washington to conduct preclinical studies for its SNS-101 program. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

IPO date 2021-02-04
ISIN US81728A1088
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.senseibio.com
Цена ао 1.04
Change price per day: +3.92% (0.4792)
Change price per week: +10.69% (0.4499)
Change price per month: -10.35% (0.5555)
Change price per 3 month: -10.35% (0.5555)
Change price per half year: -20.96% (0.6301)
Change price per year: -28.03% (0.692)
Change price per 3 year: -91.31% (5.73)
Change price per 5 year: 0% (0.498)
Change price per 10 year: 0% (0.498)
Change price per year to date: +5.96% (0.47)
All parameters

Underestimation

Title Value Grade
P/S 0 0
P/BV 0.2886 10
P/E 0 0
EV/EBITDA -0.3268 0
Total: 3.75

Efficiency

Title Value Grade
ROA, % -45.85 0
ROE, % -52.55 0
Total: 0

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA -0.1701 10
Total: 10

Growth impulse

Title Value Grade
Yield Revenue, % 0 0
Yield Ebitda, % 169.24 10
Yield EPS, % -20.78 0
Total: 5.6
More

Institutions Volume Share, %
Newtyn Management, LLC 1572023 6.27
Vanguard Group Inc 573651 2.29
Renaissance Technologies, LLC 143508 0.57
Geode Capital Management, LLC 136318 0.54
Bridgeway Capital Management, Inc. 112900 0.45
Duquesne Family Office LLC 100000 0.4
Bank of America Corporation 90788 0.36
Millennium Management LLC 38295 0.15
Blackrock Inc. 34813 0.14
Northern Trust Corporation 26049 0.1



Head Job title Payment Year of birth
Mr. John K. Celebi M.B.A. President, CEO & Director 882.28k 1972 (53 years)
Dr. Edward Van der Horst Ph.D. Chief Scientific Officer 630.81k 1974 (51 year)
Ms. Lora Pike Vice President of Investor Relations & Communications N/A
Mr. Christopher W. Gerry J.D. Senior VP, General Counsel & Secretary N/A
Ms. Stephanie Krebs M.B.A., M.S. Chief Business Officer N/A 1978 (47 years)
Dr. Aaron Weitzman FACP, M.D., Ph.D. Chief Medical Officer N/A
Mr. Josiah Craver Senior VP of Finance, Principal Financial Officer & Principal Accounting Officer

Address: United States, Rockville. MD, 1405 Research Boulevard - open in Google maps, open in Yandex maps
Website: https://www.senseibio.com